Could Nafamostat or Gabexate Prevent the Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis? / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 232-238, 2012.
Artigo
em Coreano
| WPRIM
| ID: wpr-147874
ABSTRACT
BACKGROUND/AIMS:
ERCP is the most common procedure for the diagnosis and treatment of bile duct and pancreatic disease, but Post-ERCP pancreatitis makes poor outcome in some cases. The protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to ERCP, but there is some debate. We tried to evaluate the efficacy of gabexate and nafamostat for the prevention of post-ERCP pancreatitis.METHODS:
Two hundred forty two patients (73 patients in the gabexate group, 88 patients in the nafamostat group and 81 patients in the placebo group) were included in the study after selective exclusion. The incidence of pancreatitis after ERCP was compared among groups.RESULTS:
The incidence of pancreatitis were 6.8% in the gabexate group, 5.7% in the nafamostat group and 6.2% in the placebo group (p=0.954).CONCLUSIONS:
There was no meaningful difference among the gabexate, nafamostat and placebo group.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pancreatite
/
Efeito Placebo
/
Inibidores de Serina Proteinase
/
Inquéritos e Questionários
/
Colangiopancreatografia Retrógrada Endoscópica
/
Gabexato
/
Guanidinas
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Adulto
/
Idoso
/
Aged80
/
Feminino
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS